Real-World Study of Cisplatin, Etoposide, and Bleomycin Chemotherapy Regimen in Gestational Trophoblastic Neoplasia

Table 1

Baseline Values of GTN patients who received BEP chemotherapy ().

N (percentile) Mothers	Primary treatment group ()	Salvage treatment group ()
Median age (range)	37 (29.75, 46)	34 (27, 40)
<40 years	36 (54.5)	21 (72.4)
≥40 years	30 (45.5)	8 (27.6)
Antecedent pregnancy
Hydatidiform mole	46 (69.7)	22 (75.9)
Abortion	14 (21.2)	3 (10.3)
Term pregnancy	6 (9.1)	4 (13.8)
Interval
<4 months	43 (65.2)	18 (62.1)
4–6 months	10 (15.2)	6 (20.7)
7–12 months	2 (3.0)	2 (6.9)
>12 months	11 (16.7)	3 (10.3)
Pretreatment β-hCG level
<1,000	5 (7.6)	10 (34.5)
1,000–<10,000	22 (33.3)	5 (17.2)
10,000–<100,000	21 (31.8)	10 (34.5)
>100,000	18 (27.3)	4 (13.8)
Previous chemotherapy
Yes	0	29
No	66	0
Tumor size (in cm)
<3	34 (51.5)	21 (72.4)
3-5	18 (27.2)	4 (13.8)
≥5	14 (21.2)	4 (13.8)
Site of metastasis
Vagina	1 (1.52)	0 (0)
Cervix	2 (3.03)	0 (0)
Adnexa	3 (4.55)	0 (0)
Lung	50 (75.8)	18 (62.1)
Brain	0 (0)	1 (3.45)
Humerus	1 (1.52)	0 (0)
FIGO stage
I	10 (15.2)	10 (34.5)
II	5 (7.6)	0
III	50 (75.8)	18 (62.1)
IV	1 (1.52)	1 (3.45)
Prognostic score	6 (3.5,8)	5 (3,9)
Low-risk	35 (53)	18 (62.1)
High-risk	31 (47)	11 (37.9)

Note: BEP: cisplatin, etoposide, and bleomycin; GTN: gestational trophoblastic neoplasia; FIGO: International Federation of Gynecology and Obstetrics.